baber/WOPTO huggingface dataset:
Patent NZ-588082-A (NZ)
Title: Plant disease controlling composition and method for controlling plant disease
Inventor: SOMA MASATO
IPC: A01N47/24
Filed: 2009-03-24
Abstract: Disclosed is a composition comprising an imidazolone compound represented by general formula (I) and at least one of dimoxystrobin, trifloxystrobin, azoxystrobin or pyraclostrobin. The composition is used to control plant diseases
Patent NZ-588909-A (NZ)
Title: Iminopyridine derivatives and use thereof
Inventor: YOSHIDA MASATO
IPC: A61P13/02
Filed: 2009-04-22
Abstract: Disclosed herein is are 2-imino-pyridine-3-carboxamide compounds for formula (I), wherein the substituents are as defined within the specification (in particular 5-chloro-1-[5-chloro-2-(methylsulfonyl)benzyl]-2-imino-1,2-dihydropyridine-3-carboxamide; 5-chloro-1-[5-chloro-2-thylsulfinyl)benzyl]-2-imino-1,2-dihydropyridine-3-carboxamide; 5-chloro-1-[5-fluoro-2-(methylsulfonyl)benzyl]-2-imino-1,2-dihydropyridine-3-carboxamide; 5-chloro-1-[2-(ethylsulfonyl)-5-fluorobenzyl]-2-imino-1,2-dihydropyridine-3-carboxamide ), processes for their preparation, compositions/pharmaceutical agents comprising said compounds and uses thereof. Said compounds are useful for their selective (alpha) á1D adrenergic receptor antagonistic action and are therefore useful as an agent for the prophylaxis or treatment of a lower urinary tract disease.
Patent NZ-591019-A (NZ)
Title: A hinge that is biased towards a retained position by a magnetic force
Inventor: STUART MICHAEL CHRISTOPHER
IPC: E05D5/02
Filed: 2008-08-06
Abstract: 591019 A hinge including a first hinge member including a first magnetic element; and a second hinge member including a second magnetic element, wherein the first and second hinge members are hingedly mounted to each other. The first and second hinge members are substantially maintained in a retained position via magnetic force between the first and second magnetic elements.
Patent NZ-593717-A (NZ)
Title: Method for constructing water barriers and coastal protection
Inventor: VAN DEN BROECK MARC
IPC: E02B3/06
Filed: 2009-12-17
Abstract: 593717 Disclosed is a method for constructing a water barrier or breakwater in relatively deep water. A core of quarry run is arranged on the underwater bottom and is provided with a protective layer of stones or concrete blocks At least at the position of the water barrier, the underwater bottom is raised using bottom material, the underwater bottom being raised gradually from the natural level thereof up to a position in the vicinity of the water barrier, whereby the raising has an inclination. The underwater bottom is raised with bottom material prior to the core being arranged and is raised to a height such that the average water depth at the position of the water barrier decreases by 20 to 80%. The underwater bottom is raised to a water depth which does not exceed 50% of the closure depth.
Patent NZ-597140-A (NZ)
Title: Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
Inventor: GINGRICH DIANE E
IPC: A61K31/4196
Filed: 2010-06-04
Abstract: 597140 Disclosed herein are 1,2,3-triazolo[1,5-a]pyridine derivatives of formula II wherein the substituents are defined in the specification, for use in the treatment of a hyperproliferative disease for which inhibition of at least one of JAK2 or FAK is indicated. Preferred embodiments of the compound include the following: 4-{ 3-[8-(4-methanesulfonyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridine-2-ylamino]phenyl} -piperidine-1-carboxylic acid tert-butyl ester; (3-methanoesulfonyl-phenyl)-[8-(4-methanesulfonyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridine-2-yl]-amine; and 3-[2-(quinolin-6-ylamino)-[1,2,4]triazolo[1,5-a]pyridine-8-yl]-1H-pyridin-2-one.
Patent NZ-602126-A (NZ)
Title: Ophthalmic Solution for Treating Ocular Infection Comprising Levofloxacin or Salt Thereof or Solvate of the Same, Method for Treating Ocular Infection, Levofloxacin or Salt Thereof or Solvate of the Same, and Use Thereof
Inventor: NAGANO TAKASHI
IPC: A61K31/5383
Filed: 2010-12-16
Abstract: 602126 Disclosed herein is the use of levofloxacin (I) or a salt thereof or a solvate of the same for manufactring an ophthalmic solution for treating an ocular infection, comprising levofloxacin or a salt thereof or a solvate of the same at a concentration of 1.5% (w/v) as an active ingredient, wherein one drop per one eye of the ophthalmic solution is to be instilled three times a day. The features of the present invention cure bacterial conjunctivitis in a shorter time than instillation of a 0.5% (w/v) ophthalmic solution three times a day, which is the conventional dosage or dose regimen, and do not to increase the rate of occurrence of side effects. Curing the ocular infection in a short time leads to shortening of the duration of exposure of the ocular-infection-causing bacterium to levofloxacin. Therefore, the levofloxacin ophthalmic solution in the dosage or dose regimen of the present invention is eventually expected to suppress emergence of the resistant bacterium resulting from the long-term use of the levofloxacin ophthalmic solution in the conventional dosage or dose regimen. In addition, it is confirmed that the levofloxacin ophthalmic solution in the dosage or dose regimen of the present invention directly inhibits the ocular-infection-causing bacterium such as Staphylococcus aureus from becoming resistant to levofloxacin, which results from the short-term use of the levofloxacin ophthalmic solution in the conventional dosage or dose regimen.
Patent NZ-602366-A (NZ)
Title: Novel composition for treatment of essential thrombocythemia
Inventor: STRIEDER GEORG
IPC: A61K9/20
Filed: 2011-03-25
Abstract: The present disclosure relates to a novel pharmaceutical composition free of gastric coating comprising anagrelide hydrochloride in combination with a non-pH dependent polymer and a pharmaceutically acceptable water soluble acid and its use for the treatment of essential thrombocythemia, wherein the non-pH dependent polymer is selected from the group polyacrylacids, cellulose derivatives and polyacrylamids, and wherein the amount of the non pH dependent polymer is 1.5 to 2.5 fold of anagrelide (w/w). The acid may be one of adipic acid, ascorbic acid, citric acid, fumaric acid, malic acid, succinic acid, tartaric acid and mixtures thereof. In a particular embodiment the composition comprises anagrelide HCl, polyacrylacid, citric acid, microcrystalline cellulose and magnesium stearate.
Patent NZ-607694-A (NZ)
Title: Production method of intermediate compound for synthesizing medicament
Inventor: KIM BONG CHAN
IPC: C07D471/04
Filed: 2011-08-25
Abstract: The disclosure relates to a method for preparing a compound of formula (2) through a coupling reaction followed by a cyclisation reaction using compounds (4) and (5). This compound has a chiral centre and a piperidine with an oxo group bound to it and is used as an intermediate in the preparation of a compound which exhibits good inhibitory activity against dipeptidyl peptidase IV enzyme and may be used to treat diseases including diabetes (particularly type II diabetes) and obesity. The disclosure also relates to methods for preparing the compound of formula (4) and (5).
Patent NZ-609577-A (NZ)
Title: Breast wrap
Inventor: DE VERE PHILIPPA
IPC: A61F13/14
Filed: 2012-01-18
Abstract: 609577 A nursing wrap has upper and lower independently adjustable hook and look fasteners 106a,b and 107a,b for adjusting tightness of the wrap as worn. Removable absorbent pad(s) (not shown) are also disclosed.
Patent NZ-617765-A (NZ)
Title: Substituted pyridopyrazines as novel syk inhibitors
Inventor: SU WEI-GUO
IPC: C07D471/04
Filed: 2012-06-07
Abstract: Disclosed are pyridopyrazine compounds of formula (I) where the substituents are as defined herein, for example 3-(7-(4-(dimethylamino)phenyl)pyrido[4,3-b]pyrazin-5-ylamino)propanamide and N-((1-methyl piperidin-3-yl)methyl)-7-(4-morpholinophenyl)pyrido[4,3-b]pyrazin-5-amine and pharmaceutical compositions thereof. Also disclosed are methods of use of the compounds for example in the treatment of Syk kinase mediated diseases such as allergic asthma, allergic rhinitis, rheumatoid arthritis, multiple sclerosis, lupus, systemic lupus, erythematosus, lymphoma, B cell lymphoma, T cell lymphoma, leukemia, myelodysplasic syndrome, anemia, leucopenia, neutropenia, thrombocytopenia, granuloctopenia, pancytoia or idiopathic thrombocytopenic purpura.
Patent NZ-621895-A (NZ)
Title: A prefabricated movement joint system for concrete floors
Inventor: EVE PATRICK
IPC: E04C5/16
Filed: 2014-02-28
Abstract: A prefabricated movement joint system 2 for a concrete floor slab arrangement, where the system 2 is configured to be arranged in a joint to be formed between a first concrete floor slab 1a and a second concrete floor slab 1b in the concrete floor slab arrangement. The joint system 2 comprises a first top edge rail for providing edge protection in two planes for a first upper edge 15a of the first concrete floor slab 1a in the joint to be formed between the first concrete floor slab 1a and the second concrete floor slab 1b in the concrete floor slab arrangement, a second top edge rail for providing edge protection in two planes for a second upper edge 15b of the second concrete floor slab 1b in the joint to be formed between the first concrete floor slab 1a and the second concrete floor slab 1b in the concrete floor slab arrangement, and a divider plate 4 of metal or other material to be arranged in the joint to be formed at least partly between the first concrete floor slab 1a and the second concrete floor slab 1b in the concrete floor slab arrangement and at least partly between the first top edge rail 15a and the second top edge rail 15b. The first top edge rail 15a of the prefabricated movement joint system 2 comprises a first rail portion 3a and a second rail portion. The first rail portion 3a of the first top edge rail is to be arranged essentially parallel with a top face of the first concrete floor slab 1a. The second rail portion of the first top edge rail is to be arranged essentially parallel with a joint face facing the joint to be formed between the first concrete floor slab 1a and the second concrete floor slab 1b. The first rail portion 3a is provided in an essentially right angle in relation to the second edge rail portion so that the first top edge rail has an essentially L-shaped cross section form. The first top edge rail has a plurality of anchors 6 to be cast into concrete of the first concrete floor slab to anchor the first top edge rail in the first concrete floor slab. At least one anchor 6 of the plurality of anchors has been formed by cutting and plastically deforming the material forming the second rail portion of the first top edge rail so that the at least one anchor 6 is an integral part of the second rail portion of the first top edge rail and consist of material that has been used forming the second rail portion of the first top edge rail.
Patent NZ-629636-A (NZ)
Title: Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
Inventor: MOHAN RAJU
IPC: C07D417/04
Filed: 2013-02-28
Abstract: Disclosed are compounds of formula A, E, and F, wherein the substituents are as defined in the specification. The compounds are liver X receptor (LXR) modulators useful in the treatment of dermal diseases, disorders or conditions. Examples of compounds of formula A, E, and F are: 1-(2-chlorophenyl)-5-(5-(3-(methylsulfonyl)phenyl)-1,3,4-oxadiazol-2-yl)-1H-pyrazole-3-carboxylic acid methylthiomethyI 2-(4-bromo-5-(3’-(methylsulfonyl)biphenyl-4-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate chloromethyl 2-(5-(5-(3-(methylsulfonyl)phenyl)thiophen-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate
Patent NZ-700933-A (NZ)
Title: Modeling compounds and methods of making and using the same
Inventor: DOANE JR LINWOOD E
IPC: B44C3/04
Filed: 2013-04-12
Abstract: Modeling compounds and methods for making the same are described. The modeling compounds, in some embodiments, comprise about 20% to about 40% by weight starch-based binder, and about 0.15% to about 1.2% by weight microspheres dispersed throughout the compounds. In some embodiments, the modeling compound further comprises vinylpyrrolidone polymers.
Patent NZ-706944-A (NZ)
Title: A packaging assembly
Inventor: WALLS SAM
IPC: B65B65/00
Filed: 2013-11-14
Abstract: A packaging assembly (1) having a frame (2) operatively associated with a first conveyor (3) and a second conveyor (4). The first conveyor (3) being adapted to deliver products (100) to said assembly and defining a product loading plane (AA). The second conveyor (4) being adapted to deliver cartons (6) to said assembly and defining a carton loading plane (BB). The cartons having a base and side walls extending upwardly from said base to an open end spaced from said base and adapted to receive said products in use. A tilt member (20) is operatively associated with said carton conveyor. The tilt member adapted to receive a said carton at a predetermined location along said carton conveyor, and move said carton from the carton loading plane (BB) to a product input plane (CC). A first arm (30) having a first loading magazine (32) to receive in use product from said product conveyor. A second arm (40) having a second loading magazine (42) to receive in use product from said product conveyor. The first and second arms being spaced apart to permit simultaneous operation of said arms. The arms being operatively associated with each other, to permit consecutive loading of product into said respective magazines and to deliver said magazines consecutively to said opening of respective said cartons located consecutively at said product input plane.
Patent NZ-710190-A (NZ)
Title: Method and apparatus for the electrical activation of a catalyst
Inventor: CHEN ED
IPC: H01F27/42
Filed: 2014-03-13
Abstract: Solid catalyst activation typically requires energy to be applied, either through chemical, electrochemical means, or the application of heat and pressure. This is required because reactions need thermodynamic energy to occur. However, because electrons are the primary carriers of chemical reaction and chemical bonding energy, electrochemical reactions may occur at much lower temperatures than heat and pressure as a means to activate solid catalysts. Yet the narrow range of temperatures in which aqueous reactions may occur, and the high energies required for other forms of electrochemical reactions to occur, as well as the relatively low rates displayed by electrochemical activation of catalyst has limited the usefulness of this means of catalyst activation. Furthermore, the need for an anode and a cathode has led to problems in maintaining the efficiency of the catalysts on the electrodes, as corrosion, deactivation, and sensitivity to electrolyte is a major problem. In order to address these difficulties, in accordance with some embodiments of the present invention, there is provided a reaction chamber comprising: a catalyst that, in use, is wired to a power source in electrical short circuit configuration with a current limiting circuit in the power supply; and a reaction volume in which the catalyst is disposed and wherein reactants are introduced while a current is introduced across the short circuited catalyst.
Patent NZ-719248-A (NZ)
Title: Dali control system and method
Inventor: O’NEILL PETER
IPC: H04Q5/22
Filed: 2014-12-24
Abstract: Disclosed is an Electronic Control Gear (ECG) for use in a Digital Addressable Lighting Interface (DALI) system. In a broad aspect, the ECG is configured to transmit a forward frame to control one or more other ECGs on the DALI network. The forward frame is generated in accordance with a control input provided by a control device not connected to the DALI network. In a specific form, the control input is received by the ECG at a switched active input of the ECG. Also disclosed is a DALI system comprising at least one ECG disclosed herein, as well as a method of controlling other ECGs.
Patent NZ-731735-A (NZ)
Title: Anti-pd-1 antibodies and methods of use thereof
Inventor: RAJPAL ARVIND
IPC: C07K16/28
Filed: 2015-12-02
Abstract: The present invention provides structurally defined antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases. The structurally defined anti-PD-1 antibody comprises HCDR1 of GYTFTSYWIN; HCDR2 of NIX1PGSSX2TNYNEKFKN, wherein X1 is Y or W, and X2 is L, I, or S; HCDR3 of LX1TGTFAY, wherein X1 is L or S; LCDR1 of KSSQSLX1DSX2NOKNFLT, wherein X1 is W or L, and X2 is G or T; LCDR2 of WTSX1RES, wherein X1 is T or Y; and LCDR3 of QNDYX1YPX2T, wherein X1 is F or S, and X2 is L or H.
Patent NZ-732875-A (NZ)
Title: Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
Inventor: KOVACEVICH BRIAN ROBERT
IPC: A61K39/395
Filed: 2012-05-21
Abstract: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
Patent NZ-745142-A (NZ)
Title: Stationary ergometric exercise device
Inventor: BACANOVIC MILAN
IPC: A63B71/06
Filed: 2017-01-11
Abstract: A stationary ergometric exercise device (10) comprises afoot-operable drive including alternately operable drive elements in the form of foot-driven pedals (18) mounted via pedal cranks (20) to opposite sides of a drive wheel (22). A flywheel (24) is coupled to the drive wheel (22) via a gear mechanism (26), the flywheel including a magnetic rim (38). The exercise device (10) includes a brake device (40) in the form of one or more permanent magnets (44a,44b) mounted for movement by means of a motor (42) towards and away from the magnetic rim (38) of the flywheel (24) so as to selectively adjust a braking force applied to the flywheel (24) by means of the or each permanent magnet (44a,44b). A measuring unit (58) is provided for measuring, in use, at least, one of drive force applied via the drive and the torque related to it, together with a measuring device (66) for measuring, in use, cadence. A command module (72) is connected to the measuring unit (58), the measuring device 20 (66) and the motor (42) of the brake device (40), and a communications module (74) is connected to the command module (72) and configured to receive command signals and transmit those command signals to the command module (72) and configured to transmit feedback signals received from the command module (72) reporting user performance. The command module (72) is configured to calculate a predetermined performance profile on receipt of performance characteristic data in the form of command signals from the communications module, said performance characteristic data including information concerning two or more cycling parameters, and wherein the command module is configured to receive measurements from the measuring unit (58) and the measuring device (66) and to use those measurements to calculate a power output of the user and to compare the power output of the user against the predetermined performance profile and to control the motor so as to move the one or more permanent magnets (44a, 44b) relative to the magnetic rim (38) of the flywheel (24) in order to adjust the braking force applied by the one or more permanent magnets (44a, 44b) and thereby tune the measurements received from the measuring unit (58) and the measuring device (66) so as to adjust the power output of the user calculated by the command module (72) to conform with the predetermined performance profile, at the measured cadence.
Patent NZ-747942-A (NZ)
Title: Synbiotics combination for brain improvement
Inventor: GARSSEN JOHAN
IPC: A61K35/74
Filed: 2013-11-04
Abstract: The invention relates to nutritional compositions with Bifidobacterium breve and non-digestible oligosaccharides selected from the group consisting of fructo-oligosaccharides, galacto-oligosaccharides, gluco- oligosaccharides, arabino-oligosaccharides, mannan-oligosaccharides, xylo-oligosaccharides, fuco-oligosaccharides, arabinogalacto- oligosaccharides, glucomanno-oligosaccharides, galactomanno- oligosaccharides, sialic acid comprising oligosaccharides and uronic acid oligosaccharides for use in improving cognitive or behavioral performance, cognitive or behavioral development, social interaction and/or neuroinflammation in infants or toddlers. Also claimed is the use of a nuritional compositions including Bifidobacterium breve, at least one non digestible oligosaccharide, glutamine in the form of free amino acids and/or glutamine containing dipeptide and/or glutaime containing tripeptide and LC-PUFA in the form or arachidonic acid and/or docosahexaenoic acid. Also claimed is a kit of parts comprising a first container comprising glutamine, and a non-digestible oligosaccharide and a second container comprising Bifidobacterium breve.
Patent NZ-763909-A (NZ)
Title: Concentration method and device
Inventor: MENGYUAN FAN
IPC: A23C9/142
Filed: 2020-04-24
Abstract: A method for concentrating dairy products, comprising a step of performing reverse osmosis concentration treatment on raw milk using a reverse osmosis membrane; the reverse osmosis concentration treatment comprises a low-pressure reverse osmosis membrane concentration treatment (1411) and a high-pressure reverse osmosis membrane concentration treatment (1412); wherein the low-pressure reverse osmosis membrane treatment comprises a multi-stage concentration treatment, the multi-stage concentration treatment of the low-pressure reverse osmosis membrane treatment is a 1- to 14-stage concentration treatment; wherein the pressure used in each stage of the multi-stage concentration treatment of the low-pressure reverse osmosis membrane treatment is different; in the low-pressure reverse osmosis membrane treatment, the pressure used in the first three stages is 1 to 40 bar, the pressure used in the fourth and subsequent stages is 40 to 50 bar; wherein the high-pressure reverse osmosis membrane treatment comprises a multi-stage concentration treatment, the multi-stage concentration treatment of the high-pressure reverse osmosis membrane treatment is a 1- to 6-stage concentration treatment; wherein the pressure used in each stage of the multi-stage concentration treatment of the high-pressure reverse osmosis membrane treatment is different; the pressure used in the high-pressure reverse osmosis membrane treatment is 60 to 200 bar. The invention allows production of a higher concentration dairy product with lower energy consumption than prior art methods.
Patent NZ-793365-A (NZ)
Title: Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof
Inventor: YAO YIHONG
IPC: A61K35/17
Filed: 2021-03-17
Abstract: The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and a scFv targeting CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention targets CD19 and/or CD20 positive cells and can be used to treat CD19 and/or CD20 positive B- cell lymphoma, leukemia and other diseases.